Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PPP1R15B_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PPP1R15B_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PPP1R15B_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PPP1R15B_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PPP1R15B_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003096815 | Oral cavity | OSCC | endoplasmic reticulum unfolded protein response | 55/7305 | 74/18723 | 6.91e-10 | 1.75e-08 | 55 |
GO:00163119 | Oral cavity | OSCC | dephosphorylation | 220/7305 | 417/18723 | 6.33e-09 | 1.34e-07 | 220 |
GO:003530319 | Oral cavity | OSCC | regulation of dephosphorylation | 80/7305 | 128/18723 | 6.10e-08 | 1.10e-06 | 80 |
GO:00069849 | Oral cavity | OSCC | ER-nucleus signaling pathway | 36/7305 | 46/18723 | 6.49e-08 | 1.16e-06 | 36 |
GO:19001019 | Oral cavity | OSCC | regulation of endoplasmic reticulum unfolded protein response | 26/7305 | 30/18723 | 9.63e-08 | 1.66e-06 | 26 |
GO:003530420 | Oral cavity | OSCC | regulation of protein dephosphorylation | 60/7305 | 90/18723 | 9.75e-08 | 1.67e-06 | 60 |
GO:190357319 | Oral cavity | OSCC | negative regulation of response to endoplasmic reticulum stress | 33/7305 | 44/18723 | 1.31e-06 | 1.74e-05 | 33 |
GO:00435554 | Oral cavity | OSCC | regulation of translation in response to stress | 18/7305 | 20/18723 | 3.28e-06 | 3.92e-05 | 18 |
GO:007121615 | Oral cavity | OSCC | cellular response to biotic stimulus | 129/7305 | 246/18723 | 1.20e-05 | 1.23e-04 | 129 |
GO:00435584 | Oral cavity | OSCC | regulation of translational initiation in response to stress | 13/7305 | 14/18723 | 4.31e-05 | 3.71e-04 | 13 |
GO:01404674 | Oral cavity | OSCC | integrated stress response signaling | 18/7305 | 22/18723 | 5.05e-05 | 4.23e-04 | 18 |
GO:00702623 | Oral cavity | OSCC | peptidyl-serine dephosphorylation | 16/7305 | 19/18723 | 7.05e-05 | 5.60e-04 | 16 |
GO:00364995 | Oral cavity | OSCC | PERK-mediated unfolded protein response | 15/7305 | 18/18723 | 1.53e-04 | 1.07e-03 | 15 |
GO:19001024 | Oral cavity | OSCC | negative regulation of endoplasmic reticulum unfolded protein response | 13/7305 | 15/18723 | 2.07e-04 | 1.36e-03 | 13 |
GO:00353073 | Oral cavity | OSCC | positive regulation of protein dephosphorylation | 29/7305 | 45/18723 | 4.85e-04 | 2.86e-03 | 29 |
GO:19038975 | Oral cavity | OSCC | regulation of PERK-mediated unfolded protein response | 10/7305 | 11/18723 | 5.78e-04 | 3.30e-03 | 10 |
GO:004366617 | Oral cavity | OSCC | regulation of phosphoprotein phosphatase activity | 35/7305 | 58/18723 | 8.06e-04 | 4.32e-03 | 35 |
GO:00109984 | Oral cavity | OSCC | regulation of translational initiation by eIF2 alpha phosphorylation | 9/7305 | 10/18723 | 1.36e-03 | 6.62e-03 | 9 |
GO:001092110 | Oral cavity | OSCC | regulation of phosphatase activity | 46/7305 | 84/18723 | 2.43e-03 | 1.07e-02 | 46 |
GO:00353065 | Oral cavity | OSCC | positive regulation of dephosphorylation | 34/7305 | 59/18723 | 2.86e-03 | 1.24e-02 | 34 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PPP1R15B | SNV | Missense_Mutation | novel | c.1677N>A | p.Phe559Leu | p.F559L | Q5SWA1 | protein_coding | tolerated(0.07) | probably_damaging(0.999) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | | SD |
PPP1R15B | SNV | Missense_Mutation | | c.171G>C | p.Glu57Asp | p.E57D | Q5SWA1 | protein_coding | deleterious_low_confidence(0.04) | benign(0.073) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
PPP1R15B | SNV | Missense_Mutation | | c.1861G>A | p.Asp621Asn | p.D621N | Q5SWA1 | protein_coding | tolerated(0.1) | benign(0.149) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PPP1R15B | SNV | Missense_Mutation | | c.1341N>A | p.Asp447Glu | p.D447E | Q5SWA1 | protein_coding | tolerated(0.2) | possibly_damaging(0.693) | TCGA-B6-A0IJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PPP1R15B | SNV | Missense_Mutation | | c.742N>C | p.Val248Leu | p.V248L | Q5SWA1 | protein_coding | deleterious(0.03) | benign(0.159) | TCGA-E9-A244-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
PPP1R15B | SNV | Missense_Mutation | novel | c.1531G>C | p.Glu511Gln | p.E511Q | Q5SWA1 | protein_coding | tolerated(0.3) | benign(0.177) | TCGA-LL-A5YM-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unspecific | letrozole | PD |
PPP1R15B | insertion | Frame_Shift_Ins | novel | c.1228_1229insCC | p.Glu410AlafsTer17 | p.E410Afs*17 | Q5SWA1 | protein_coding | | | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PPP1R15B | insertion | Frame_Shift_Ins | novel | c.1226_1227insTGGCCTTCCAAAGTGCTGGGATTACAGGCGTG | p.Glu410GlyfsTer27 | p.E410Gfs*27 | Q5SWA1 | protein_coding | | | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PPP1R15B | insertion | Frame_Shift_Ins | novel | c.1024_1025insGTCCATTGTGGCCATTTCTGAGTGTC | p.Asn342SerfsTer33 | p.N342Sfs*33 | Q5SWA1 | protein_coding | | | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PPP1R15B | insertion | Frame_Shift_Ins | novel | c.181_182insTTCTTAGTTGGGAATATTCTGAAAGAATTGGTAGCATAAAGGG | p.Ser61IlefsTer95 | p.S61Ifs*95 | Q5SWA1 | protein_coding | | | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |